DGX insider transaction filings
QUEST DIAGNOSTICS INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-03. Screen DGX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 12 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 3 filings by 3 insiders — 34,277 shares, $8,316,571 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: sale of 16,010 shares @ $242.88 ($3,888,437) by PREVOZNIK MICHAEL E, filed 2026-08-31.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| PREVOZNIK MICHAEL E — SVP & General Counsel | 1 | — | 3 legs · 22,677 sh · $5,513,083 | 3 |
| Davis J. E. — CEO and President, Director | 1 | — | 1 leg · 10,000 sh · $2,427,200 | — |
| DELANEY MARK E — SVP & Chief Commercial Officer | 2 | — | 1 leg · 1,600 sh · $376,288 | 1 |
| CARTER ROBERT B — Director | 1 | — | — | 1 |
| Gregg Vicky B — Director | 1 | — | — | 1 |
| KUPPUSAMY KARTHIK — SVP, Clinical Solutions | 1 | — | — | 1 |
| Lassiter Wright III — Director | 1 | — | — | 1 |
| MAIN TIMOTHY L — Director | 1 | — | — | 1 |
| Plewman Patrick — SVP for Diagnostic Services | 1 | — | — | 1 |
| SAMAD SAM — Executive Vice President & CFO | 1 | — | — | 1 |
+1 more insider in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — QUEST DIAGNOSTICS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Davis J. E. — CEO and President, Director | Sale (S): 10,000 @ $242.72 | EDGAR |
| 2026-08-31 | 4 | PREVOZNIK MICHAEL E — SVP & General Counsel | Option exercise (M): 22,677 @ $112.17 · Sale (S): 16,010 @ $242.88 · Sale (S): 6,237 @ $243.63 · Sale (S): 430 @ $244.51 · Gift (G): 1,000 @ $0 · Option exercise (M): 22,677 (derivative) @ $112.17 | EDGAR |
| 2026-07-29 | 4 | DELANEY MARK E — SVP & Chief Commercial Officer | Sale (S): 1,600 @ $235.18 | EDGAR |
| 2026-07-27 | 4 | CARTER ROBERT B — Director | Code (L): 11 @ $206.80 | EDGAR |
| 2026-07-27 | 4 | KUPPUSAMY KARTHIK — SVP, Clinical Solutions | Code (L): 37 @ $206.81 | EDGAR |
| 2026-07-27 | 4 | SAMAD SAM — Executive Vice President & CFO | Grant/award (A): 102 @ $206.81 | EDGAR |
| 2026-07-27 | 4 | MAIN TIMOTHY L — Director | Code (L): 21 @ $206.81 | EDGAR |
| 2026-07-27 | 4 | Plewman Patrick — SVP for Diagnostic Services | Code (L): 46 @ $206.81 | EDGAR |
| 2026-07-27 | 4 | Gregg Vicky B — Director | Grant/award (A): 72 @ $206.81 | EDGAR |
| 2026-07-27 | 4 | DELANEY MARK E — SVP & Chief Commercial Officer | Code (L): 34 @ $206.81 | EDGAR |
| 2026-07-27 | 4 | Lassiter Wright III — Director | Code (L): 6 @ $206.81 | EDGAR |
| 2026-07-02 | 4 | WENTWORTH TIMOTHY C — Director | Grant/award (A): 144 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | KUPPUSAMY KARTHIK — SVP, Clinical Solutions | Option exercise (M): 3,320 @ $127.72 · Option exercise (M): 4,827 @ $121.81 · Sale (S): 8,147 @ $200 · Option exercise (M): 3,320 (derivative) @ $127.72 · Option exercise (M): 4,827 (derivative) @ $121.81 | EDGAR |
| 2026-06-02 | 4 | Davis J. E. — CEO and President, Director | Sale (S): 10,000 @ $194.14 | EDGAR |
| 2026-05-21 | 4 | Lassiter Wright III — Director | Grant/award (A): 1,142 @ $0 | EDGAR |
| 2026-05-21 | 4 | Diaz Luis — Director | Grant/award (A): 1,142 @ $0 | EDGAR |
| 2026-05-21 | 4 | Doi Tracey — Director | Grant/award (A): 1,142 @ $0 | EDGAR |
| 2026-05-21 | 4 | Gregg Vicky B — Director | Grant/award (A): 1,142 @ $0 | EDGAR |
| 2026-05-21 | 4 | WENTWORTH TIMOTHY C — Director | Grant/award (A): 1,142 @ $0 | EDGAR |
| 2026-05-21 | 4 | MORRISON DENISE M — Director | Grant/award (A): 1,142 @ $0 | EDGAR |
| 2026-05-21 | 4 | RING TIMOTHY M — Director | Grant/award (A): 1,142 @ $0 | EDGAR |
| 2026-05-21 | 4 | CARTER ROBERT B — Director | Grant/award (A): 1,142 @ $0 | EDGAR |
| 2026-05-21 | 4 | MAIN TIMOTHY L — Director | Grant/award (A): 1,142 @ $0 | EDGAR |
| 2026-05-21 | 4 | PFEIFFER GARY M — Director | Grant/award (A): 1,142 @ $0 | EDGAR |
| 2026-04-24 | 4 | SAMAD SAM — Executive Vice President & CFO | Grant/award (A): 108 @ $194.70 | EDGAR |
| 2026-04-24 | 4 | Plewman Patrick — SVP for Diagnostic Services | Code (L): 49 @ $194.70 | EDGAR |
| 2026-04-24 | 4 | Gregg Vicky B — Director | Grant/award (A): 68 @ $194.70 | EDGAR |
| 2026-04-24 | 4 | CARTER ROBERT B — Director | Code (L): 7 @ $194.70 | EDGAR |
| 2026-04-24 | 4 | Lassiter Wright III — Director | Code (L): 6 @ $194.70 | EDGAR |
| 2026-04-24 | 4 | KUPPUSAMY KARTHIK — SVP, Clinical Solutions | Code (L): 39 @ $194.70 | EDGAR |
| 2026-04-24 | 4 | DELANEY MARK E — SVP & Chief Commercial Officer | Code (L): 37 @ $194.70 | EDGAR |
| 2026-04-02 | 4 | WENTWORTH TIMOTHY C — Director | Grant/award (A): 198 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | WENTWORTH TIMOTHY C — Director | Grant/award (A): 215 @ $0 | EDGAR |
| 2026-03-06 | 4 | SAMAD SAM — Executive Vice President & CFO | Grant/award (A): 13,947 @ $204.86 · Tax withholding (F): 7,720 @ $204.86 | EDGAR |
| 2026-03-06 | 4 | Doherty Catherine T. — EVP, Regional Businesses | Grant/award (A): 11,364 @ $204.86 · Tax withholding (F): 5,806 @ $204.86 · Sale (S): 5,558 @ $206.21 | EDGAR |
| 2026-03-06 | 4 | DELANEY MARK E — SVP & Chief Commercial Officer | Grant/award (A): 5,682 @ $204.86 · Tax withholding (F): 2,326 @ $204.86 | EDGAR |
| 2026-03-06 | 4 | PREVOZNIK MICHAEL E — SVP & General Counsel | Grant/award (A): 7,232 @ $204.86 · Tax withholding (F): 3,354 @ $204.86 · Sale (S): 3,878 @ $206.21 | EDGAR |
| 2026-03-06 | 4 | Davis J. E. — CEO and President, Director | Grant/award (A): 51,652 @ $204.86 · Tax withholding (F): 26,414 @ $204.86 | EDGAR |
| 2026-03-06 | 4 | Plewman Patrick — SVP for Diagnostic Services | Grant/award (A): 5,682 @ $204.86 · Tax withholding (F): 2,827 @ $204.86 · Sale (S): 2,855 @ $206.21 | EDGAR |
| 2026-03-06 | 4 | Deppe Michael J — SVP, Corp. Controller & CAO | Grant/award (A): 1,473 @ $204.86 · Tax withholding (F): 750 @ $204.86 | EDGAR |
| 2026-03-06 | 4 | KUPPUSAMY KARTHIK — SVP, Clinical Solutions | Grant/award (A): 6,200 @ $204.86 · Sale (S): 2,628 @ $204.86 | EDGAR |
| 2026-03-04 | 4 | Doherty Catherine T. — EVP, Regional Businesses | Tax withholding (F): 648 @ $204.86 · Sale (S): 632 @ $207.73 | EDGAR |
| 2026-03-04 | 4 | SAMAD SAM — Executive Vice President & CFO | Tax withholding (F): 869 @ $204.86 | EDGAR |
| 2026-03-04 | 4 | PREVOZNIK MICHAEL E — SVP & General Counsel | Tax withholding (F): 288 @ $204.86 · Sale (S): 526 @ $207.73 | EDGAR |
| 2026-03-04 | 4 | Davis J. E. — CEO and President, Director | Tax withholding (F): 2,968 @ $204.86 · Sale (S): 10,000 @ $212.52 | EDGAR |
| 2026-03-04 | 4 | Plewman Patrick — SVP for Diagnostic Services | Tax withholding (F): 230 @ $204.86 · Sale (S): 410 @ $207.73 | EDGAR |
| 2026-03-04 | 4 | KUPPUSAMY KARTHIK — SVP, Clinical Solutions | Tax withholding (F): 205 @ $204.86 | EDGAR |
| 2026-03-04 | 4 | DELANEY MARK E — SVP & Chief Commercial Officer | Tax withholding (F): 188 @ $204.86 | EDGAR |
| 2026-03-04 | 4 | Deppe Michael J — SVP, Corp. Controller & CAO | Tax withholding (F): 88 @ $204.86 | EDGAR |
| 2026-02-20 | 4 | Lassiter Wright III — Director | Code (L): 7 @ $183.51 | EDGAR |
Recent 8-K events — QUEST DIAGNOSTICS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-10 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-21 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-22 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DGX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →